k141_118459_2	SARG|gi|542061059|gb|ERI11611.1|	33.7	190	284	316	2.31e-26	104
k141_118459_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.8	192	284	307	1.03e-25	102
k141_118459_2	SARG|gi|447195835|ref|WP_001273091.1|	30.7	192	284	306	7.06e-24	97.4
k141_118459_2	SARG|gi|500194536|ref|WP_011867743.1|	31.6	190	284	306	1.35e-23	96.7
k141_118459_2	SARG|ZP_04081918	30.2	192	284	306	1.87e-23	96.3
k141_118459_2	SARG|gi|447195836|ref|WP_001273092.1|	30.2	192	284	306	1.87e-23	96.3
k141_118459_2	SARG|U82085.gene.p01	26.0	204	284	552	1.78e-11	63.2
k141_118459_2	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.7	148	284	505	2.38e-10	59.7
k141_118459_2	SARG|gi|924337096|ref|WP_053474708.1|	27.6	156	284	492	1.01e-09	57.8
k141_118459_2	SARG|gi|951389844|ref|WP_057765492.1|	26.3	156	284	492	1.36e-09	57.4
k141_3153_13	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	36.1	122	388	314	7.08e-13	67.8
k141_3153_56	SARG|gb|AAV85982.1|ARO:3000535|macB	39.8	191	263	644	1.41e-29	115
k141_3153_56	SARG|YP_001373621	27.1	210	263	318	7.43e-18	80.5
k141_9497_1	SARG|AF139725.gene.p01	49.6	123	127	214	3.92e-33	114
k141_9497_1	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	49.6	123	127	214	1.11e-32	113
k141_9497_1	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	49.6	123	127	214	1.11e-32	113
k141_9497_1	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	48.8	123	127	214	3.12e-32	112
k141_9497_1	SARG|AAK91782	48.8	123	127	214	3.12e-32	112
k141_9497_1	SARG|AAG21695	48.0	123	127	214	8.79e-32	110
k141_9497_1	SARG|AAF24171	48.0	123	127	214	1.75e-31	110
k141_9497_1	SARG|gb|AAF63432|ARO:3003744|vatF	47.9	119	127	221	2.93e-31	109
k141_9497_1	SARG|U19459.gene.p01	45.5	123	127	212	1.05e-29	105
k141_9497_1	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	47.2	123	127	214	1.10e-29	105
k141_9497_2	SARG|gi|751930065|ref|WP_041144773.1|	33.5	182	191	648	1.26e-19	84.7
k141_9497_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.2	192	191	307	3.36e-17	76.6
k141_9497_2	ResF|poxtA-Ef_1_WP094899500.1_1	30.5	174	191	538	7.42e-15	70.9
k141_9497_2	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	30.5	174	191	543	7.45e-15	70.9
k141_9497_2	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	30.5	174	191	543	7.45e-15	70.9
k141_9497_2	SARG|gb|AVI44920.1|ARO:3004470|poxtA	31.6	155	191	542	3.78e-11	60.1
k141_9497_2	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	31.6	155	191	544	3.79e-11	60.1
k141_9497_2	SARG|AXF35727.1	24.6	179	191	497	3.19e-07	48.5
k141_78046_9	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	32.6	340	536	373	6.64e-32	125
k141_78046_20	CARD|gb|ATC67679.1|ARO:3000838|arlR	48.2	220	225	219	9.15e-63	194
k141_78046_20	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	225	225	232	9.17e-44	145
k141_78046_20	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.0	223	225	223	2.01e-43	144
k141_78046_20	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.7	218	225	228	4.61e-43	144
k141_78046_20	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.5	224	225	220	5.21e-43	143
k141_78046_20	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.5	224	225	220	7.36e-43	143
k141_78046_20	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.8	222	225	219	1.01e-42	142
k141_78046_20	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.6	224	225	231	1.41e-42	142
k141_78046_20	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	222	225	219	8.02e-42	140
k141_78046_20	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	224	225	220	2.89e-39	134
k141_78046_21	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.9	288	471	359	1.04e-19	89.4
k141_78046_21	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	27.3	238	471	357	8.23e-19	86.7
k141_78046_21	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	27.3	238	471	357	8.23e-19	86.7
k141_78046_29	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	28.4	313	461	593	5.65e-21	94.7
k141_78046_29	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	25.1	335	461	664	8.07e-17	82.0
k141_78046_29	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	25.7	334	461	665	1.07e-16	81.6
k141_78046_29	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	25.4	334	461	665	1.43e-16	81.3
k141_78046_29	SARG|gb|CCC86795.1|ARO:3001209|mecC	25.1	335	461	665	1.43e-16	81.3
k141_78046_29	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	24.3	334	461	665	4.45e-16	79.7
k141_78046_29	SARG|gb|AQX82857.1|ARO:3004185|mecD	23.9	426	461	678	5.77e-15	76.3
k141_78046_29	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	22.8	294	461	633	4.14e-06	48.1
k141_78046_33	SARG|AY082011.1.gene6.p01	35.7	272	318	323	1.03e-33	125
k141_78046_33	SARG|gi|552942232|ref|WP_023043160.1|	35.7	272	318	323	2.00e-33	124
k141_78046_33	SARG|gi|749574782|ref|WP_040203616.1|	35.6	275	318	323	1.05e-32	122
k141_78046_33	SARG|NP_878015	34.9	275	318	322	2.03e-31	119
k141_78046_33	SARG|gi|738848198|ref|WP_036737307.1|	34.5	275	318	323	2.88e-31	118
k141_78046_33	SARG|gi|985522333|ref|WP_060811962.1|	34.4	270	318	323	1.50e-30	116
k141_78046_33	SARG|AAD41881	32.4	278	318	323	2.90e-30	115
k141_78046_33	SARG|AAD51059	32.4	278	318	323	4.03e-30	115
k141_78046_33	SARG|Q47748	34.4	270	318	323	4.03e-30	115
k141_78046_33	SARG|gb|AAB05626.1|ARO:3002943|vanHB	34.4	270	318	323	4.03e-30	115
k141_112547_5	ResF|penA_1_AF515059_1	28.3	598	742	581	1.95e-41	159
k141_112547_5	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	22.9	598	742	674	1.59e-11	66.6
k141_112547_5	SARG|gb|BAI83385.1|ARO:3003440|mecB	22.3	524	742	674	2.76e-11	65.9
k141_112547_52	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	35.8	240	356	355	8.49e-33	124
k141_112547_52	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	35.8	240	356	355	8.49e-33	124
k141_112547_52	SARG|ACM47285	35.8	240	356	363	9.79e-33	124
k141_112547_52	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	36.0	247	356	356	4.44e-32	122
k141_112547_52	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	35.4	240	356	356	2.27e-31	120
k141_112547_52	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	33.8	240	356	355	4.16e-30	117
k141_112547_52	SARG|BAE96115	33.8	240	356	355	4.16e-30	117
k141_112547_54	SARG|gi|445996719|ref|WP_000074574.1|	31.2	218	300	309	1.01e-32	121
k141_112547_54	SARG|gi|445996710|ref|WP_000074565.1|	30.7	218	300	309	1.01e-32	121
k141_112547_54	SARG|gi|895736250|emb|COF64653.1|	30.7	218	300	309	2.75e-32	120
k141_112547_54	SARG|gi|446110087|ref|WP_000187942.1|	30.7	218	300	309	2.75e-32	120
k141_112547_54	SARG|gi|445996714|ref|WP_000074569.1|	30.7	218	300	309	2.75e-32	120
k141_112547_54	SARG|gi|895808656|emb|COR83787.1|	30.7	218	300	309	2.75e-32	120
k141_112547_54	SARG|gi|445996696|ref|WP_000074551.1|	31.7	218	300	309	3.84e-32	120
k141_112547_54	SARG|gi|814314593|emb|CKF49145.1|	30.3	218	300	309	5.35e-32	119
k141_112547_54	SARG|gi|445996724|ref|WP_000074579.1|	30.7	218	300	309	7.47e-32	119
k141_112547_54	SARG|gi|884875933|emb|CKG93789.1|	30.7	218	300	309	7.47e-32	119
k141_112547_58	SARG|gi|926351744|ref|WP_053683383.1|	29.4	252	402	648	8.76e-25	105
k141_112547_58	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.0	232	402	582	1.37e-24	104
k141_112547_58	SARG|gi|772774655|ref|WP_045322518.1|	28.9	246	402	620	1.50e-24	104
k141_112547_58	SARG|gi|917203192|ref|WP_051809904.1|	29.3	246	402	620	2.02e-24	104
k141_112547_58	SARG|gi|917229923|ref|WP_051836635.1|	29.3	246	402	620	2.02e-24	104
k141_112547_58	SARG|gi|926376632|ref|WP_053705806.1|	28.9	246	402	620	2.72e-24	103
k141_112547_58	SARG|gi|926286457|ref|WP_053623344.1|	29.4	228	402	605	4.77e-24	103
k141_112547_58	SARG|gi|799286378|ref|WP_045936958.1|	28.9	246	402	620	4.91e-24	103
k141_112547_58	SARG|gi|917127754|ref|WP_051734466.1|	28.9	246	402	620	4.91e-24	103
k141_112547_58	SARG|gi|926294973|ref|WP_053631154.1|	28.9	246	402	620	4.91e-24	103
k141_112547_62	SARG|gi|486458841|gb|EOE03251.1|	49.1	55	299	237	6.97e-09	54.3
k141_81543_5	SARG|gb|AAK76137.1|ARO:3000024|patA	28.6	210	236	564	5.17e-14	69.7
k141_81543_5	SARG|gi|926400371|ref|WP_053728483.1|	25.4	224	236	603	1.86e-09	56.2
k141_81543_5	SARG|gi|655401130|ref|WP_028800283.1|	26.9	197	236	599	8.17e-09	54.3
k141_81543_5	SARG|gi|947982677|ref|WP_056642336.1|	27.0	211	236	626	1.11e-08	53.9
k141_81543_5	SARG|gi|639892676|ref|WP_024755698.1|	27.0	211	236	631	1.12e-08	53.9
k141_81543_5	SARG|gi|944152509|ref|WP_055644808.1|	26.5	211	236	616	3.61e-08	52.4
k141_81543_5	SARG|gi|493394434|ref|WP_006350564.1|	26.0	215	236	602	4.81e-08	52.0
k141_81543_5	SARG|gi|663350985|ref|WP_030349761.1|	25.7	206	236	613	4.84e-08	52.0
k141_81543_5	SARG|gi|664352659|ref|WP_030880307.1|	27.0	196	236	601	6.46e-08	51.6
k141_81543_5	SARG|gi|662754041|ref|WP_030125200.1|	27.0	196	236	601	6.46e-08	51.6
k141_81543_14	SARG|YP_302230	21.9	383	461	451	2.82e-23	100
k141_34564_2	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	67.7	470	530	1162	4.53e-218	634
k141_34564_2	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	65.1	501	530	1186	1.22e-214	626
k141_34564_2	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	65.1	501	530	1186	1.22e-214	626
k141_128306_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	636	634	655	2.76e-117	363
k141_128306_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	3.88e-117	362
k141_128306_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	5.46e-117	362
k141_128306_4	SARG|gb|AKA86814|ARO:3003746|optrA	34.1	636	634	655	5.46e-117	362
k141_128306_4	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	7.68e-117	362
k141_128306_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	1.08e-116	361
k141_128306_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	1.08e-116	361
k141_128306_4	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	1.08e-116	361
k141_128306_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	1.52e-116	361
k141_128306_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.1	636	634	655	1.52e-116	361
k141_128306_12	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	24.0	208	262	293	7.05e-12	63.2
k141_128306_12	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	25.9	216	262	505	9.29e-12	63.5
k141_128306_12	SARG|FR772051.1.gene9.p01	26.1	218	262	524	5.58e-11	61.2
k141_128306_12	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	25.8	217	262	504	7.37e-11	60.8
k141_128306_12	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.5	234	262	655	2.08e-09	56.6
k141_128306_12	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.1	232	262	655	2.08e-09	56.6
k141_128306_12	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.1	232	262	655	2.08e-09	56.6
k141_128306_12	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.6	250	262	655	1.21e-08	54.3
k141_128306_12	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.6	242	262	655	1.21e-08	54.3
k141_128306_12	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.7	232	262	655	1.62e-08	53.9
k141_72169_10	SARG|gb|ABA71733.1|ARO:3002972|vanTG	36.9	374	399	712	5.74e-78	253
k141_72169_10	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	37.9	377	399	712	1.83e-73	241
k141_72169_10	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	36.2	376	399	700	1.84e-63	214
k141_72169_10	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.7	374	399	711	1.11e-60	207
k141_72169_10	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	35.5	375	399	700	1.83e-60	206
k141_72169_10	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	34.7	375	399	706	1.40e-58	201
k141_72169_10	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	32.9	374	399	366	2.05e-58	193
k141_72169_10	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	34.9	375	399	700	2.49e-58	201
k141_72169_10	SARG|FJ872411.1.gene43.p01	33.5	373	399	702	2.45e-56	195
k141_72169_10	SARG|AAY67970	32.0	375	399	698	1.64e-55	193
k141_72169_11	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.3	418	425	441	5.04e-47	166
k141_9863_4	SARG|gi|1025843957|ref|WP_063576302.1|	38.8	160	263	287	1.47e-30	114
k141_9863_4	SARG|AF155139.2.gene4.p01	36.3	160	263	293	3.24e-30	113
k141_9863_4	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	39.0	159	263	299	9.91e-30	112
k141_9863_4	SARG|FJ349556.1.gene4.p01	38.1	160	263	233	1.82e-29	110
k141_9863_4	SARG|CAB61224	37.6	157	263	297	3.62e-29	110
k141_9863_4	SARG|AAY52007	38.4	159	263	294	4.77e-29	110
k141_9863_4	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	38.4	159	263	296	4.96e-29	110
k141_9863_4	NCBI|WP_107309513.1|1|1|vanY-M|vanY-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-M|AMR|glycopeptide	38.1	160	263	287	5.81e-29	110
k141_9863_4	SARG|ACP19238	36.5	159	263	296	1.38e-27	106
k141_9863_4	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	36.5	159	263	296	1.38e-27	106
k141_53494_2	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	58.5	299	299	481	1.38e-114	338
k141_53494_2	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	57.9	297	299	451	1.32e-110	327
k141_53494_2	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	56.6	297	299	451	6.02e-109	322
k141_56853_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	48.3	526	755	575	1.92e-159	473
k141_56853_11	SARG|gb|AAK76137.1|ARO:3000024|patA	37.9	514	755	564	2.10e-109	343
k141_56853_11	SARG|gi|930482089|ref|WP_054228897.1|	34.1	367	755	599	9.14e-60	211
k141_56853_11	SARG|gi|985844137|ref|WP_060895163.1|	34.1	367	755	599	9.14e-60	211
k141_56853_11	SARG|gi|748767925|ref|WP_040019608.1|	34.3	367	755	623	1.94e-59	211
k141_56853_11	SARG|gi|943938624|ref|WP_055567802.1|	33.5	367	755	602	8.99e-59	209
k141_56853_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.9	536	755	664	1.00e-58	210
k141_56853_11	SARG|gi|505420018|ref|WP_015607120.1|	33.5	367	755	603	6.17e-58	206
k141_56853_11	SARG|gi|928900436|ref|WP_053931243.1|	33.2	367	755	600	8.03e-58	206
k141_56853_11	SARG|gi|664579989|ref|WP_031094015.1|	33.2	367	755	601	8.18e-58	206
k141_50654_8	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.7	502	590	582	2.79e-64	220
k141_50654_8	SARG|gi|799286378|ref|WP_045936958.1|	30.7	544	590	620	1.49e-60	211
k141_50654_8	SARG|gi|917127754|ref|WP_051734466.1|	30.7	544	590	620	1.49e-60	211
k141_50654_8	SARG|gi|926376632|ref|WP_053705806.1|	30.7	544	590	620	1.49e-60	211
k141_50654_8	SARG|gi|926294973|ref|WP_053631154.1|	30.7	544	590	620	1.49e-60	211
k141_50654_8	SARG|gi|648667297|ref|WP_026359044.1|	30.4	542	590	605	1.57e-60	210
k141_50654_8	SARG|gi|926356413|ref|WP_053687351.1|	30.7	544	590	620	2.06e-60	210
k141_50654_8	SARG|gi|926345639|ref|WP_053677539.1|	30.7	544	590	620	2.06e-60	210
k141_50654_8	SARG|gi|516574297|ref|WP_017949361.1|	32.7	495	590	620	2.06e-60	210
k141_50654_8	SARG|gi|917203192|ref|WP_051809904.1|	30.5	544	590	620	3.95e-60	209
k141_50654_9	SARG|gi|664556405|ref|WP_031071225.1|	30.4	494	579	602	8.54e-68	229
k141_50654_9	SARG|gi|944009777|ref|WP_055601444.1|	29.7	546	579	628	2.00e-66	226
k141_50654_9	SARG|gi|944152509|ref|WP_055644808.1|	28.8	546	579	616	2.21e-65	223
k141_50654_9	SARG|gi|516795764|ref|WP_018105258.1|	29.2	497	579	601	1.19e-64	221
k141_50654_9	SARG|gi|497748188|ref|WP_010062372.1|	29.4	493	579	605	1.79e-64	221
k141_50654_9	SARG|gi|517347347|ref|WP_018522839.1|	28.4	489	579	601	2.30e-64	220
k141_50654_9	SARG|gi|516574297|ref|WP_017949361.1|	29.4	489	579	620	4.59e-64	220
k141_50654_9	SARG|gi|947982677|ref|WP_056642336.1|	28.7	540	579	626	5.13e-64	220
k141_50654_9	SARG|gi|639892676|ref|WP_024755698.1|	28.7	540	579	631	5.63e-64	220
k141_50654_9	SARG|gi|1033217078|gb|OAR27197.1|	30.1	488	579	601	6.17e-64	219
k141_50654_15	SARG|gi|740856590|ref|WP_038641842.1|	32.2	236	345	648	9.97e-23	98.2
k141_50654_15	SARG|gi|757799695|ref|WP_043016897.1|	32.2	236	345	648	1.34e-22	97.8
k141_50654_15	SARG|gi|1045891604|ref|WP_065554100.1|	32.2	236	345	648	1.34e-22	97.8
k141_50654_15	SARG|gi|507082903|ref|WP_016153652.1|	32.2	236	345	648	1.34e-22	97.8
k141_50654_15	SARG|gi|835233765|ref|WP_047410073.1|	29.9	261	345	648	1.34e-22	97.8
k141_50654_15	SARG|gi|507086196|ref|WP_016156937.1|	32.2	236	345	648	1.34e-22	97.8
k141_50654_15	SARG|gi|922960663|ref|WP_053388845.1|	32.2	236	345	648	1.81e-22	97.4
k141_50654_15	SARG|gi|754951242|ref|WP_042307417.1|	32.2	236	345	648	2.44e-22	97.1
k141_50654_15	SARG|gi|493734654|ref|WP_006683876.1|	32.2	236	345	648	2.44e-22	97.1
k141_50654_15	SARG|gi|696368937|ref|WP_032943949.1|	31.8	236	345	648	5.95e-22	95.9
k141_50654_19	SARG|gi|693054987|ref|WP_032223114.1|	32.5	249	233	648	2.80e-19	85.1
k141_50654_19	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.6	203	233	307	5.28e-19	82.8
k141_50654_19	SARG|gi|1035706844|ref|WP_064548272.1|	34.1	223	233	648	8.96e-17	77.8
k141_50654_19	SARG|gb|AAK76137.1|ARO:3000024|patA	29.2	219	233	564	5.89e-15	72.4
k141_122545_14	SARG|gi|917127754|ref|WP_051734466.1|	34.1	577	596	620	1.53e-95	304
k141_122545_14	SARG|gi|799286378|ref|WP_045936958.1|	34.0	577	596	620	5.95e-95	302
k141_122545_14	SARG|gi|926294973|ref|WP_053631154.1|	34.0	577	596	620	5.95e-95	302
k141_122545_14	SARG|gi|919568551|ref|WP_052871170.1|	36.3	490	596	620	8.35e-95	302
k141_122545_14	SARG|gi|860594225|ref|WP_048475168.1|	33.5	579	596	620	8.35e-95	302
k141_122545_14	SARG|gi|926356413|ref|WP_053687351.1|	34.0	577	596	620	8.35e-95	302
k141_122545_14	SARG|gi|926345639|ref|WP_053677539.1|	34.0	577	596	620	8.35e-95	302
k141_122545_14	SARG|gi|926376632|ref|WP_053705806.1|	34.0	579	596	620	1.17e-94	301
k141_122545_14	SARG|gi|496018010|ref|WP_008742581.1|	33.4	577	596	623	1.26e-94	301
k141_122545_14	SARG|gi|917203192|ref|WP_051809904.1|	33.8	577	596	620	1.64e-94	301
k141_1532_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	26.2	539	678	1024	5.47e-55	202
k141_1532_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	26.2	539	678	1024	5.47e-55	202
k141_1532_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	26.2	539	678	1024	9.96e-55	201
k141_1532_1	SARG|gb|CAA53189|ARO:3000521|mupA	26.2	539	678	1024	9.96e-55	201
k141_1532_7	SARG|gi|922960663|ref|WP_053388845.1|	40.7	221	338	648	8.44e-46	164
k141_1532_7	SARG|gi|757799695|ref|WP_043016897.1|	40.7	221	338	648	1.16e-45	163
k141_1532_7	SARG|gi|1045891604|ref|WP_065554100.1|	40.7	221	338	648	1.16e-45	163
k141_1532_7	SARG|gi|507082903|ref|WP_016153652.1|	40.7	221	338	648	1.16e-45	163
k141_1532_7	SARG|gi|740856590|ref|WP_038641842.1|	40.7	221	338	648	1.16e-45	163
k141_1532_7	SARG|gi|835233765|ref|WP_047410073.1|	40.7	221	338	648	1.61e-45	163
k141_1532_7	SARG|gi|754951242|ref|WP_042307417.1|	40.7	221	338	648	1.61e-45	163
k141_1532_7	SARG|gi|493734654|ref|WP_006683876.1|	40.7	221	338	648	1.61e-45	163
k141_1532_7	SARG|gi|491270241|ref|WP_005128370.1|	40.7	221	338	648	2.22e-45	162
k141_1532_7	SARG|gi|507086196|ref|WP_016156937.1|	40.7	221	338	648	2.22e-45	162
k141_137913_2	SARG|gb|AAK76137.1|ARO:3000024|patA	28.6	220	310	564	1.64e-14	72.8
k141_137913_2	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	24.9	201	310	505	1.33e-10	60.8
k141_137913_2	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.4	205	310	550	1.06e-09	58.2
k141_137913_2	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	23.3	202	310	504	7.61e-09	55.5
k141_137913_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	25.6	250	318	307	5.59e-20	87.4
k141_137913_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.0	241	318	575	3.18e-15	75.1
k141_137913_3	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	28.3	244	318	293	9.01e-15	72.4
k141_137913_11	SARG|gi|487407385|ref|WP_001675419.1|	28.6	245	265	648	2.34e-19	86.3
k141_137913_11	SARG|gi|487661511|ref|WP_001751648.1|	28.6	245	265	648	2.34e-19	86.3
k141_137913_11	SARG|YP_002214869	28.6	245	265	648	2.34e-19	86.3
k141_137913_11	SARG|YP_001588793	28.2	245	265	648	2.34e-19	86.3
k141_137913_11	SARG|gi|923061916|ref|WP_053445667.1|	28.6	245	265	648	2.34e-19	86.3
k141_137913_11	SARG|YP_002044935	28.6	245	265	648	3.16e-19	85.9
k141_137913_11	SARG|gi|835666879|ref|WP_047606339.1|	28.6	245	265	648	3.16e-19	85.9
k141_137913_11	SARG|gi|555254264|ref|WP_023237471.1|	28.6	245	265	648	3.16e-19	85.9
k141_137913_11	SARG|gi|959101689|ref|WP_058107049.1|	28.6	245	265	648	3.16e-19	85.9
k141_137913_11	SARG|gi|746482713|ref|WP_039520502.1|	28.2	245	265	648	4.27e-19	85.5
k141_66917_1	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	48.4	153	159	451	2.18e-43	147
k141_66917_1	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	45.8	153	159	481	2.73e-40	140
k141_66917_1	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	44.4	153	159	451	1.90e-38	134
k141_66917_8	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.3	230	220	232	2.77e-44	147
k141_66917_8	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.3	230	220	232	2.77e-44	147
k141_66917_8	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	217	220	219	5.42e-44	145
k141_66917_8	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	217	220	220	5.58e-44	145
k141_66917_8	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	217	220	220	1.57e-43	144
k141_66917_8	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.1	231	220	229	4.03e-43	144
k141_66917_8	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	220	219	4.31e-43	143
k141_66917_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.9	217	220	219	6.09e-43	143
k141_66917_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.3	223	220	231	8.49e-43	143
k141_66917_8	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.3	223	220	232	3.47e-42	141
k141_66917_9	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.7	244	488	368	1.27e-31	124
k141_66917_9	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.3	244	488	367	3.22e-31	122
k141_66917_9	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.8	255	488	381	1.28e-29	118
k141_66917_9	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.8	255	488	381	1.28e-29	118
k141_66917_9	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.2	250	488	380	1.72e-29	118
k141_66917_9	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	250	488	380	1.72e-29	118
k141_66917_9	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.1	262	488	370	9.61e-29	115
k141_66917_9	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	31.6	225	488	359	1.51e-28	115
k141_66917_9	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.3	238	488	381	2.12e-28	115
k141_66917_9	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.3	238	488	381	2.12e-28	115
k141_66917_32	SARG|gb|AAK76137.1|ARO:3000024|patA	36.5	85	231	564	9.98e-09	53.9
k141_66917_32	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.3	72	231	293	1.35e-07	50.1
k141_1840_4	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	60.8	492	493	494	6.17e-216	604
k141_1840_4	SARG|gi|902795376|ref|WP_049664555.1|	57.9	492	493	492	1.79e-212	595
k141_1840_4	SARG|gi|926256269|ref|WP_053594535.1|	57.5	492	493	492	1.68e-210	590
k141_1840_4	SARG|gi|1032346815|ref|WP_064200323.1|	57.7	492	493	492	1.94e-209	587
k141_1840_4	SARG|gi|1003765182|ref|WP_061463312.1|	56.9	492	493	492	2.76e-209	587
k141_1840_4	SARG|gi|944535691|ref|WP_055747198.1|	57.7	492	493	492	5.55e-209	586
k141_1840_4	SARG|gi|924348018|ref|WP_053483923.1|	57.1	492	493	492	5.55e-209	586
k141_1840_4	SARG|gi|494215524|ref|WP_007131565.1|	57.5	492	493	492	1.12e-208	585
k141_1840_4	SARG|gi|507043215|ref|WP_016114558.1|	56.7	492	493	492	1.29e-207	583
k141_1840_4	SARG|gi|737454728|ref|WP_035434889.1|	56.5	492	493	492	1.29e-207	583
k141_1840_14	SARG|gb|AAC75314.1|ARO:3003578|pmrF	27.9	315	322	322	1.46e-35	130
k141_1840_24	SARG|gi|752682279|ref|WP_041330231.1|	46.0	350	356	349	7.73e-101	300
k141_1840_24	SARG|gi|1028100561|ref|WP_063856696.1|	44.6	350	356	349	1.77e-99	297
k141_1840_24	SARG|gi|765411304|ref|WP_044689514.1|	43.4	350	356	349	4.59e-97	291
k141_1840_24	SARG|DQ212986.1.gene8.p01	43.4	350	356	349	9.20e-97	290
k141_1840_24	SARG|gi|405945042|pdb|4FU0|A	43.4	350	356	357	1.18e-96	290
k141_1840_24	SARG|AAF71281	43.1	350	356	349	5.22e-96	288
k141_1840_24	SARG|CAB61227	44.3	359	356	343	2.54e-92	278
k141_1840_24	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	43.1	369	356	366	4.73e-90	273
k141_1840_24	SARG|gi|749574464|ref|WP_040203371.1|	44.0	359	356	343	9.28e-90	272
k141_1840_24	SARG|AF277571.gene.p01	41.1	360	356	343	5.26e-89	270
k141_1840_36	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	35.8	265	458	355	1.46e-33	128
k141_1840_36	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	35.8	265	458	355	1.46e-33	128
k141_1840_36	SARG|ACM47285	35.8	265	458	363	1.69e-33	128
k141_1840_36	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.8	263	458	356	3.42e-31	122
k141_1840_36	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.8	263	458	356	4.71e-31	121
k141_1840_36	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	34.0	265	458	355	6.36e-31	121
k141_1840_36	SARG|BAE96115	34.0	265	458	355	6.36e-31	121
k141_1840_36	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.5	263	458	356	3.17e-30	119
k141_1840_36	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	35.9	184	458	209	8.60e-24	97.8
k141_1840_43	SARG|gi|495736522|ref|WP_008461101.1|	30.3	211	323	648	7.44e-18	83.2
k141_1840_43	SARG|gi|746253210|ref|WP_039301529.1|	30.3	211	323	648	1.00e-17	82.8
k141_1840_43	SARG|gi|896325272|ref|WP_049294291.1|	30.7	231	323	648	1.34e-17	82.4
k141_1840_43	SARG|gi|696368937|ref|WP_032943949.1|	29.7	232	323	648	3.26e-17	81.3
k141_1840_43	SARG|gi|851913025|ref|WP_048215946.1|	29.7	232	323	648	3.26e-17	81.3
k141_1840_43	SARG|gi|1001720867|ref|WP_061274204.1|	29.9	211	323	648	3.26e-17	81.3
k141_1840_43	SARG|gi|489930965|ref|WP_003834285.1|	29.7	232	323	648	3.26e-17	81.3
k141_1840_43	SARG|gi|639216333|ref|WP_024554080.1|	30.3	231	323	648	3.26e-17	81.3
k141_1840_43	SARG|YP_002850060	29.7	232	323	648	4.39e-17	80.9
k141_1840_43	SARG|gi|851922185|ref|WP_048218206.1|	29.7	212	323	648	5.89e-17	80.5
k141_1840_44	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.3	150	216	255	1.76e-18	80.1
k141_1840_44	SARG|NP_286651	35.8	190	216	648	3.73e-16	75.5
k141_1840_44	SARG|gi|446110336|ref|WP_000188191.1|	35.8	190	216	648	3.13e-15	72.8
k141_1840_44	SARG|gi|693256048|ref|WP_032359333.1|	35.8	190	216	648	4.24e-15	72.4
k141_1840_44	SARG|Q83LR7	36.3	190	216	648	4.24e-15	72.4
k141_1840_44	SARG|gi|647325472|ref|WP_025760953.1|	36.3	190	216	648	4.24e-15	72.4
k141_1840_44	SARG|gi|647323678|ref|WP_025760497.1|	36.3	190	216	648	4.24e-15	72.4
k141_1840_44	SARG|gi|1035686596|ref|WP_064530178.1|	36.3	190	216	648	4.24e-15	72.4
k141_1840_44	SARG|gi|727407986|ref|WP_033815909.1|	35.8	190	216	648	5.74e-15	72.0
k141_1840_44	SARG|gi|446110305|ref|WP_000188160.1|	36.3	190	216	648	5.74e-15	72.0
k141_132705_4	SARG|gi|736993687|ref|WP_034989673.1|	45.5	55	226	513	2.93e-08	52.4
k141_132705_4	SARG|AF024666.2.gene6.p01	45.5	55	226	513	2.93e-08	52.4
k141_132705_4	SARG|gi|171851258|emb|CAQ04234.1|	43.6	55	226	483	3.86e-08	52.0
k141_132705_4	SARG|gi|491465657|ref|WP_005323423.1|	41.8	55	226	513	7.58e-07	48.1
k141_132705_4	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	26.5	162	226	293	2.49e-06	46.2
k141_132705_5	SARG|gi|447057509|ref|WP_001134765.1|	31.1	235	258	309	1.47e-21	90.5
k141_132705_5	SARG|gi|500448961|gb|EOP61695.1|	30.5	210	258	306	3.72e-21	89.4
k141_132705_5	SARG|gi|445996719|ref|WP_000074574.1|	32.1	224	258	309	7.39e-21	88.6
k141_132705_5	SARG|gi|488120365|ref|WP_002191762.1|	29.7	229	258	309	7.39e-21	88.6
k141_132705_5	SARG|gi|488068784|ref|WP_002140181.1|	30.8	221	258	309	1.02e-20	88.2
k141_132705_5	SARG|gi|500465078|gb|EOP76697.1|	31.6	209	258	306	1.36e-20	87.8
k141_132705_5	SARG|gi|447057510|ref|WP_001134766.1|	30.8	221	258	309	1.41e-20	87.8
k141_132705_5	SARG|gi|445996723|ref|WP_000074578.1|	32.1	224	258	309	1.94e-20	87.4
k141_132705_5	SARG|gi|445996710|ref|WP_000074565.1|	30.0	210	258	309	1.94e-20	87.4
k141_132705_5	SARG|gi|488067981|ref|WP_002139378.1|	30.8	221	258	309	2.68e-20	87.0
k141_132705_11	SARG|gi|445996710|ref|WP_000074565.1|	29.8	228	232	309	1.99e-29	110
k141_132705_11	SARG|gi|445996719|ref|WP_000074574.1|	29.2	233	232	309	2.78e-29	110
k141_132705_11	SARG|gi|1043490477|ref|WP_065382463.1|	28.8	233	232	309	1.48e-28	108
k141_132705_11	SARG|gi|445996726|ref|WP_000074581.1|	28.8	233	232	309	1.48e-28	108
k141_132705_11	SARG|gi|445996723|ref|WP_000074578.1|	28.8	233	232	309	1.48e-28	108
k141_132705_11	SARG|gi|507054395|ref|WP_016125339.1|	28.8	233	232	309	1.48e-28	108
k141_132705_11	SARG|gi|507035724|ref|WP_016107411.1|	28.3	233	232	309	2.06e-28	108
k141_132705_11	SARG|gi|445996724|ref|WP_000074579.1|	28.3	233	232	309	2.06e-28	108
k141_132705_11	SARG|gi|445996729|ref|WP_000074584.1|	28.9	228	232	309	2.06e-28	108
k141_132705_11	SARG|gi|445996698|ref|WP_000074553.1|	28.3	233	232	309	2.06e-28	108
k141_113719_24	SARG|gi|489931383|ref|WP_003834702.1|	31.5	311	310	660	2.35e-47	167
k141_113719_24	SARG|gi|757799830|ref|WP_043017032.1|	31.5	311	310	660	3.25e-47	167
k141_113719_24	SARG|gi|765458296|ref|WP_044714032.1|	31.5	311	310	660	3.25e-47	167
k141_113719_24	SARG|gi|851935911|ref|WP_048224705.1|	30.9	311	310	660	6.19e-47	166
k141_113719_24	SARG|gi|489117806|ref|WP_003027650.1|	31.2	311	310	660	6.19e-47	166
k141_113719_24	SARG|ZP_04005119	31.9	313	310	660	6.19e-47	166
k141_113719_24	SARG|gi|696375142|ref|WP_032949690.1|	31.2	311	310	660	6.19e-47	166
k141_113719_24	SARG|gi|723045111|ref|WP_033545426.1|	31.9	313	310	660	8.55e-47	166
k141_113719_24	SARG|gi|1002399350|ref|WP_061382108.1|	31.2	311	310	660	8.55e-47	166
k141_113719_24	SARG|YP_002398630	31.9	313	310	660	8.55e-47	166
k141_113719_27	SARG|AXY65402.1	34.3	350	354	357	8.03e-52	174
k141_113719_29	CARD|gb|WKR28567.1|ARO:3007678|IreK	36.0	592	640	718	3.42e-96	310
k141_57424_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	33.6	274	303	1024	7.14e-48	170
k141_57424_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.6	274	303	1024	7.14e-48	170
k141_57424_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.6	274	303	1024	7.14e-48	170
k141_57424_1	SARG|gb|CAA53189|ARO:3000521|mupA	33.6	274	303	1024	7.14e-48	170
k141_57424_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	31.4	280	303	1033	2.10e-42	154
k141_57424_1	SARG|gb|AEY83581|ARO:3000510|mupB	31.4	280	303	1033	2.10e-42	154
k141_132928_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	42.5	551	580	575	8.65e-140	416
k141_132928_4	SARG|gb|AAK76137.1|ARO:3000024|patA	35.4	526	580	564	2.10e-101	317
k141_132928_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.9	537	580	582	4.34e-64	219
k141_132928_4	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.8	590	580	579	2.95e-63	217
k141_132928_4	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.3	590	580	579	5.69e-62	213
k141_132928_4	SARG|gi|917229923|ref|WP_051836635.1|	30.0	480	580	620	1.18e-59	208
k141_132928_4	SARG|gi|516574297|ref|WP_017949361.1|	27.9	549	580	620	2.26e-59	207
k141_132928_4	SARG|gi|944152509|ref|WP_055644808.1|	29.8	486	580	616	7.76e-59	206
k141_132928_4	SARG|gi|558888514|ref|WP_023543283.1|	27.9	544	580	615	1.06e-58	205
k141_132928_4	SARG|AF170880.4.gene1.p01	27.9	544	580	615	1.46e-58	205
k141_132928_5	SARG|gb|AAK76136.1|ARO:3000025|patB	32.9	583	582	588	5.30e-94	298
k141_132928_5	SARG|gb|CDO61516.1|ARO:3003949|efrB	46.6	326	582	362	3.22e-92	286
k141_132928_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.1	490	582	664	1.52e-90	291
k141_132928_5	SARG|gi|926351744|ref|WP_053683383.1|	30.5	573	582	648	2.07e-74	248
k141_132928_5	SARG|gi|496018010|ref|WP_008742581.1|	30.4	572	582	623	1.26e-73	246
k141_132928_5	SARG|gi|860594225|ref|WP_048475168.1|	30.3	574	582	620	2.30e-73	245
k141_132928_5	SARG|gi|919568551|ref|WP_052871170.1|	29.8	573	582	620	8.69e-73	243
k141_132928_5	SARG|gi|921231571|ref|WP_053176464.1|	41.4	304	582	620	1.21e-72	243
k141_132928_5	SARG|gi|917172177|ref|WP_051778889.1|	41.4	304	582	620	1.69e-72	243
k141_132928_5	SARG|gi|748767925|ref|WP_040019608.1|	32.7	572	582	623	3.49e-72	242
k141_45179_1	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	32.0	181	461	579	5.09e-15	76.3
k141_45179_1	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	30.9	181	461	579	4.91e-14	73.2
k141_45179_7	SARG|gb|AAC75314.1|ARO:3003578|pmrF	30.3	314	314	322	5.11e-40	141
k141_141633_25	SARG|gi|445996719|ref|WP_000074574.1|	23.4	205	245	309	2.80e-11	61.2
k141_141633_25	SARG|gi|445996710|ref|WP_000074565.1|	23.4	205	245	309	6.97e-11	60.1
k141_141633_25	ResF|poxtA-Ef_1_WP094899500.1_1	24.3	206	245	538	1.62e-08	53.5
k141_141633_25	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	24.3	206	245	543	1.63e-08	53.5
k141_141633_25	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	24.3	206	245	543	1.63e-08	53.5
k141_141633_35	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.2	229	233	232	3.07e-58	183
k141_141633_35	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.2	229	233	232	3.07e-58	183
k141_141633_35	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.2	226	233	228	1.41e-55	176
k141_141633_35	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.0	225	233	231	1.24e-54	174
k141_141633_35	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	228	233	231	1.24e-54	174
k141_141633_35	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.3	225	233	232	1.80e-54	173
k141_141633_35	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	228	233	231	2.48e-54	173
k141_141633_35	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	228	233	231	3.50e-54	172
k141_141633_35	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.5	228	233	231	3.50e-54	172
k141_141633_35	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	228	233	231	3.50e-54	172
k141_141633_48	SARG|GQ205627.2.gene3.p01	32.5	123	193	216	7.99e-09	52.4
k141_141633_48	SARG|AF047479.2.gene11.p01	48.3	58	193	210	2.37e-07	48.1
k141_141633_48	SARG|gi|499386493|ref|WP_011073960.1|	44.6	56	193	210	4.41e-07	47.4
k141_141633_48	SARG|AY232670.1.gene3.p01	46.6	58	193	210	8.19e-07	46.6
k141_141633_48	SARG|gb|AID93387.1|ARO:3004660|catB11	41.1	56	193	210	1.12e-06	46.2
k141_141633_48	SARG|gb|APB03220.1|ARO:3003987|VatI	30.7	114	193	210	1.12e-06	46.2
k141_141633_48	SARG|gb|CAI47810.1|ARO:3003110|catB10	41.1	56	193	210	2.07e-06	45.4
k141_141633_48	SARG|gb|ACL13298.1|ARO:3003110|catB10	41.1	56	193	210	2.07e-06	45.4
k141_141633_48	SARG|M58472.1.gene1.p01	38.2	55	193	209	9.54e-06	43.5
k141_141633_48	NCBI|WP_021018581.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	37.5	56	193	210	9.60e-06	43.5
k141_35645_8	SARG|gi|923061916|ref|WP_053445667.1|	29.9	231	336	648	7.50e-07	49.7
k141_35645_12	SARG|gb|CDO61516.1|ARO:3003949|efrB	56.4	330	597	362	3.69e-120	359
k141_35645_12	SARG|gb|AYV52072.1|ARO:3002882|lmrD	39.2	513	597	664	5.35e-119	366
k141_35645_12	SARG|gb|AAK76136.1|ARO:3000025|patB	36.4	590	597	588	6.01e-117	358
k141_35645_12	SARG|gi|926376632|ref|WP_053705806.1|	35.9	493	597	620	1.20e-94	301
k141_35645_12	SARG|gi|926294973|ref|WP_053631154.1|	35.5	496	597	620	1.20e-94	301
k141_35645_12	SARG|gi|926356413|ref|WP_053687351.1|	35.5	496	597	620	1.69e-94	301
k141_35645_12	SARG|gi|917166849|ref|WP_051773561.1|	35.1	499	597	620	2.37e-94	301
k141_35645_12	SARG|gi|917155568|ref|WP_051762280.1|	35.1	499	597	620	3.33e-94	300
k141_35645_12	SARG|gi|772774655|ref|WP_045322518.1|	35.3	496	597	620	4.67e-94	300
k141_35645_12	SARG|gi|919568551|ref|WP_052871170.1|	35.3	496	597	620	6.55e-94	300
k141_35645_13	SARG|gb|WP_104671188.1|ARO:3003948|efrA	52.7	577	581	575	1.46e-200	572
k141_35645_13	SARG|gb|AAK76137.1|ARO:3000024|patA	36.5	509	581	564	1.41e-98	310
k141_35645_13	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.8	526	581	664	7.60e-64	220
k141_35645_13	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.3	537	581	582	1.65e-61	212
k141_35645_13	SARG|gb|AAK76136.1|ARO:3000025|patB	28.0	525	581	588	3.47e-59	206
k141_35645_13	SARG|gi|948137056|ref|WP_056795395.1|	42.3	227	581	602	8.12e-57	200
k141_35645_13	SARG|gi|917203192|ref|WP_051809904.1|	40.9	254	581	620	1.52e-56	199
k141_35645_13	SARG|gi|517787730|ref|WP_018957938.1|	42.5	226	581	610	1.78e-56	199
k141_35645_13	SARG|gi|748767925|ref|WP_040019608.1|	42.5	226	581	623	2.20e-56	199
k141_35645_13	SARG|gi|926376632|ref|WP_053705806.1|	40.9	254	581	620	2.90e-56	199
k141_147753_28	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.7	684	642	703	1.80e-172	507
k141_147753_47	SARG|gi|969848384|ref|WP_058609247.1|	29.9	682	649	646	1.31e-69	237
k141_147753_47	SARG|gi|829942568|ref|WP_047368199.1|	30.0	679	649	646	1.82e-69	237
k141_147753_47	SARG|gi|493171912|ref|WP_006174388.1|	29.8	682	649	646	4.86e-69	236
k141_147753_47	SARG|gi|1022641085|ref|WP_063404331.1|	30.0	679	649	646	4.86e-69	236
k141_147753_47	SARG|gi|798928072|ref|WP_045906664.1|	30.0	679	649	646	6.74e-69	235
k141_147753_47	SARG|gi|779827732|ref|WP_045339794.1|	30.0	679	649	646	6.74e-69	235
k141_147753_47	SARG|gi|779852631|ref|WP_045348970.1|	30.0	679	649	646	9.36e-69	235
k141_147753_47	SARG|gi|836580371|ref|WP_047737758.1|	30.0	679	649	646	9.36e-69	235
k141_147753_47	SARG|gi|1028180030|ref|WP_063927084.1|	29.9	679	649	646	9.36e-69	235
k141_147753_47	SARG|gi|896106549|ref|WP_049136608.1|	30.0	679	649	646	9.36e-69	235
k141_133144_4	SARG|gb|AAS79458.1|ARO:3001302|chrB	30.4	250	275	280	1.02e-24	99.0
k141_45422_2	SARG|gi|500194536|ref|WP_011867743.1|	29.1	227	311	306	4.95e-20	87.4
k141_45422_2	SARG|gb|AAK76137.1|ARO:3000024|patA	26.3	236	311	564	9.71e-14	70.5
k141_45422_3	SARG|gi|639225329|ref|WP_024561799.1|	32.6	218	274	648	1.78e-23	98.6
k141_45422_3	SARG|gi|639218559|ref|WP_024556062.1|	32.6	218	274	648	1.78e-23	98.6
k141_45422_3	SARG|gi|554685678|ref|WP_023185565.1|	33.0	218	274	648	1.78e-23	98.6
k141_45422_3	SARG|gi|657888313|ref|WP_029592374.1|	32.1	218	274	648	3.26e-23	97.8
k141_45422_3	SARG|YP_001571041	33.0	218	274	648	3.26e-23	97.8
k141_45422_3	SARG|gi|960873409|ref|WP_058345546.1|	33.0	218	274	648	3.26e-23	97.8
k141_45422_3	SARG|gi|896325272|ref|WP_049294291.1|	32.6	218	274	648	5.97e-23	97.1
k141_45422_3	SARG|gi|446048013|ref|WP_000125868.1|	32.6	215	274	648	8.09e-23	96.7
k141_45422_3	SARG|Q83LR7	33.6	217	274	648	8.09e-23	96.7
k141_45422_3	SARG|gi|647325472|ref|WP_025760953.1|	33.6	217	274	648	8.09e-23	96.7
k141_45422_7	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.8	240	251	575	1.38e-28	112
k141_45422_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.6	228	251	664	1.95e-25	103
k141_45422_7	SARG|gb|AAK76137.1|ARO:3000024|patA	27.5	240	251	564	6.77e-24	99.0
k141_45422_7	SARG|gb|AAK76136.1|ARO:3000025|patB	30.3	228	251	588	8.16e-23	95.9
k141_45422_7	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.4	180	251	362	2.15e-20	87.8
k141_45422_7	SARG|gi|748767925|ref|WP_040019608.1|	27.1	229	251	623	1.69e-19	86.3
k141_45422_7	SARG|gi|860594225|ref|WP_048475168.1|	26.5	234	251	620	2.28e-19	85.9
k141_45422_7	SARG|gi|496018010|ref|WP_008742581.1|	27.8	237	251	623	4.19e-19	85.1
k141_45422_7	SARG|AF170880.4.gene1.p01	26.4	231	251	615	1.03e-18	84.0
k141_45422_7	SARG|gi|505420018|ref|WP_015607120.1|	27.0	233	251	603	2.54e-18	82.8
k141_45422_14	SARG|gb|AAA26793|ARO:3003748|oleC	34.3	210	295	325	2.17e-35	129
k141_45422_14	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.3	210	295	325	3.03e-35	128
k141_45422_14	SARG|gi|542061059|gb|ERI11611.1|	30.1	219	295	316	3.79e-33	122
k141_45422_14	SARG|gi|445996729|ref|WP_000074584.1|	30.2	212	295	309	9.24e-32	119
k141_45422_14	SARG|gi|1043490477|ref|WP_065382463.1|	30.2	212	295	309	9.24e-32	119
k141_45422_14	SARG|gi|445996726|ref|WP_000074581.1|	30.2	212	295	309	9.24e-32	119
k141_45422_14	SARG|gi|507054395|ref|WP_016125339.1|	30.2	212	295	309	9.24e-32	119
k141_45422_14	SARG|gi|445996724|ref|WP_000074579.1|	30.2	212	295	309	1.29e-31	118
k141_45422_14	SARG|gi|884875933|emb|CKG93789.1|	30.2	212	295	309	1.29e-31	118
k141_45422_14	SARG|gi|895808656|emb|COR83787.1|	30.2	212	295	309	1.29e-31	118
k141_61217_3	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	30.0	689	660	703	1.30e-81	271
k141_51632_2	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	26.2	221	297	346	3.97e-13	67.8
k141_51632_5	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	25.4	228	290	346	1.48e-13	68.9
k141_89049_11	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	28.7	506	706	633	1.01e-44	169
k141_89049_11	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	24.5	485	706	674	3.40e-21	97.4
k141_89049_11	SARG|gb|BAI83385.1|ARO:3003440|mecB	25.8	364	706	674	2.40e-20	94.7
k141_89049_11	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	28.1	270	706	593	1.61e-10	63.2
k141_89049_16	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.5	239	251	552	1.53e-14	71.6
k141_89049_16	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	25.7	237	251	568	1.49e-11	62.8
k141_89049_16	SARG|FR772051.1.gene9.p01	23.2	220	251	524	9.14e-10	57.4
k141_89049_16	SARG|GQ205627.2.gene1.p01	25.1	251	251	525	1.23e-09	57.0
k141_89049_16	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	233	251	655	1.33e-09	57.0
k141_89049_16	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	233	251	655	1.33e-09	57.0
k141_89049_16	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	233	251	655	1.33e-09	57.0
k141_89049_16	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	233	251	655	1.33e-09	57.0
k141_89049_16	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	233	251	655	1.33e-09	57.0
k141_89049_16	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	233	251	655	1.33e-09	57.0
k141_73666_1	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.8	116	171	258	1.12e-15	71.2
k141_73666_1	SARG|gi|817122037|ref|WP_046494699.1|	34.8	92	171	613	5.12e-10	56.2
k141_73666_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.2	230	307	582	3.69e-19	86.7
k141_73666_2	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	25.3	182	307	505	1.72e-10	60.5
k141_73666_2	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	24.9	177	307	504	4.16e-09	56.2
k141_73666_8	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	72.6	230	232	231	2.06e-128	361
k141_73666_8	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	71.3	230	232	231	5.89e-128	360
k141_73666_8	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	70.9	230	232	231	1.69e-127	358
k141_73666_8	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	72.2	230	232	231	2.40e-127	358
k141_73666_8	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	71.3	230	232	231	1.96e-126	356
k141_73666_8	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	67.1	231	232	232	1.95e-117	333
k141_73666_8	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	66.7	231	232	232	5.59e-117	332
k141_73666_8	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	59.2	233	232	233	7.72e-101	291
k141_73666_8	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	57.9	235	232	235	1.93e-99	288
k141_73666_8	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	55.8	233	232	232	8.47e-93	271
k141_73666_9	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	63.9	238	379	386	2.27e-96	291
k141_73666_9	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	63.9	238	379	386	2.27e-96	291
k141_73666_9	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	63.0	238	379	386	1.28e-95	289
k141_73666_9	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	63.0	238	379	386	1.28e-95	289
k141_73666_9	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	63.0	238	379	384	1.70e-95	289
k141_73666_9	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	63.0	238	379	384	1.70e-95	289
k141_73666_9	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	63.0	238	379	382	6.41e-95	287
k141_73666_9	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	63.0	238	379	382	6.41e-95	287
k141_73666_9	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	63.0	238	379	388	4.35e-94	285
k141_73666_9	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	63.0	238	379	388	4.35e-94	285
k141_73666_10	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.6	274	331	355	1.64e-22	95.5
k141_73666_10	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	26.6	274	331	355	1.64e-22	95.5
k141_73666_10	SARG|ACM47285	26.6	274	331	363	1.79e-22	95.5
k141_73666_10	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	26.3	274	331	355	1.32e-20	90.1
k141_73666_10	SARG|BAE96115	26.3	274	331	355	1.32e-20	90.1
k141_73666_11	SARG|YP_001779894	56.1	57	173	212	1.22e-14	67.8
k141_73666_11	SARG|YP_002861121	56.1	57	173	212	1.70e-14	67.4
k141_73666_11	SARG|YP_001389621	54.4	57	173	212	3.28e-14	66.6
k141_73666_11	SARG|YP_001785579	54.4	57	173	212	6.34e-14	65.9
k141_73666_11	SARG|AF139725.gene.p01	30.2	172	173	214	1.17e-10	57.0
k141_73666_11	SARG|AAF24171	53.1	49	173	214	2.22e-10	56.2
k141_73666_11	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	53.1	49	173	214	2.22e-10	56.2
k141_73666_11	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	53.1	49	173	214	2.22e-10	56.2
k141_73666_11	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	53.1	49	173	214	2.22e-10	56.2
k141_73666_11	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	53.1	49	173	214	2.22e-10	56.2
k141_73666_17	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	32.5	212	328	322	4.80e-28	110
k141_73666_17	SARG|DQ018711.1.gene4.p01	33.7	199	328	322	6.66e-28	109
k141_73666_17	SARG|gi|552942232|ref|WP_023043160.1|	34.7	213	328	323	9.38e-28	109
k141_73666_17	SARG|AY082011.1.gene6.p01	34.3	213	328	323	6.61e-27	107
k141_73666_17	SARG|gi|740152780|ref|WP_037997109.1|	30.4	260	328	322	2.38e-26	105
k141_73666_17	SARG|gi|737310392|ref|WP_035293250.1|	32.7	199	328	323	3.35e-26	105
k141_73666_17	SARG|AAY52004	31.6	212	328	322	4.55e-26	104
k141_73666_17	SARG|gi|738848198|ref|WP_036737307.1|	32.7	199	328	323	8.46e-25	101
k141_73666_17	SARG|Q47748	32.6	242	328	323	1.17e-24	100
k141_73666_17	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	34.2	199	328	323	1.61e-24	100
k141_73666_21	SARG|ZP_04528247	63.3	278	278	279	8.29e-116	333
k141_73666_21	SARG|ZP_03984017	62.1	272	278	288	4.40e-108	313
k141_73666_21	SARG|ZP_04433866	61.8	272	278	288	8.86e-108	313
k141_73666_21	SARG|ZP_03949893	61.8	272	278	288	8.86e-108	313
k141_73666_21	SARG|YP_002929946	61.5	273	278	282	1.11e-104	305
k141_73666_21	SARG|ZP_03945515	59.5	274	278	291	2.84e-102	299
k141_73666_21	SARG|ZP_03958019	56.6	281	278	317	1.55e-100	295
k141_73666_21	SARG|ZP_03941859	55.4	276	278	288	1.38e-99	292
k141_73666_21	SARG|ZP_03938934	55.4	276	278	288	1.38e-99	292
k141_73666_21	SARG|YP_002937728	53.5	284	278	289	5.00e-90	268
k141_77060_5	NCBI|WP_043245728.1|1|1|blaPAM-1|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-1|AMR|beta-lactam	28.7	129	214	287	4.27e-08	51.2
k141_77060_5	NCBI|WP_173179784.1|1|1|blaPAM-2|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-2|AMR|beta-lactam	29.5	129	214	287	4.27e-08	51.2
k141_77060_5	NCBI|WP_420354156.1|1|1|blaPAM-6|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-6|AMR|beta-lactam	28.7	129	214	287	4.27e-08	51.2
k141_77060_5	NCBI|WP_184489348.1|1|1|blaPAM-5|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-5|AMR|beta-lactam	28.7	129	214	287	4.27e-08	51.2
k141_77060_5	NCBI|WP_111263186.1|1|1|blaPAM-3|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-3|AMR|beta-lactam	29.5	129	214	287	5.77e-08	50.8
k141_133762_1	SARG|gi|1033151784|ref|WP_064457526.1|	25.4	213	273	614	9.36e-11	60.8
k141_133762_1	SARG|gi|987887954|ref|WP_060953374.1|	25.4	213	273	614	9.36e-11	60.8
k141_133762_1	SARG|gi|664304639|ref|WP_030834011.1|	25.4	213	273	614	9.36e-11	60.8
k141_133762_1	SARG|gi|1011069317|ref|WP_062010695.1|	25.4	213	273	614	9.36e-11	60.8
k141_133762_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	21.3	240	273	575	1.64e-10	60.1
k141_133762_1	SARG|gi|943938624|ref|WP_055567802.1|	23.0	213	273	602	1.74e-09	57.0
k141_133762_1	SARG|gi|497748188|ref|WP_010062372.1|	24.1	203	273	605	3.13e-09	56.2
k141_133762_1	SARG|gi|1045390184|ref|WP_065479071.1|	24.2	207	273	605	4.19e-09	55.8
k141_133762_1	SARG|gi|764446018|ref|WP_044369325.1|	24.2	215	273	605	1.34e-08	54.3
k141_133762_1	SARG|gi|664170108|ref|WP_030704355.1|	21.9	201	273	603	1.80e-08	53.9
k141_61544_4	SARG|L42544.gene.p01	28.6	665	694	651	2.47e-82	273
k141_61544_4	SARG|AAV80410	28.6	665	694	651	4.80e-82	272
k141_61544_4	SARG|NP_348076	27.4	676	694	652	5.29e-77	258
k141_61544_4	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.9	681	694	629	1.70e-74	251
k141_61544_4	ResF|tet(O/W)_1_AM889118_1	27.9	681	694	639	2.11e-74	251
k141_61544_4	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.9	681	694	629	3.29e-74	250
k141_61544_4	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.9	681	694	629	3.29e-74	250
k141_61544_4	ResF|tet(O/W)_4_AM889121_1	27.9	681	694	639	4.07e-74	250
k141_61544_4	ResF|tet(O/W)_5_AM889122_1	27.9	681	694	639	4.07e-74	250
k141_61544_4	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	689	694	629	6.37e-74	249
k141_21270_2	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.3	437	418	444	3.20e-57	193
k141_42859_7	SARG|gi|585355296|ref|WP_024236899.1|	39.1	225	245	648	1.59e-42	151
k141_42859_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.8	225	245	664	6.35e-22	93.2
k141_42859_7	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.4	236	245	579	9.95e-18	80.9
k141_42859_7	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.8	229	245	579	1.35e-17	80.5
k141_42859_7	SARG|gb|AAC75271.1|ARO:3003952|yojI	32.0	197	245	547	4.93e-16	75.9
k141_42859_7	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.2	227	245	351	1.42e-13	68.2
k141_42859_7	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	24.2	227	245	351	1.92e-13	67.8
k141_3089_12	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	34.2	430	433	444	6.92e-56	190
k141_3089_15	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	47.2	159	160	159	1.78e-42	137
k141_148184_3	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	469	604	639	3.34e-27	115
k141_148184_3	SARG|ABV82118	24.8	501	604	639	4.45e-27	115
k141_148184_3	SARG|ZP_03989103	24.2	501	604	639	1.05e-26	114
k141_148184_3	SARG|ABV82120	24.2	501	604	639	1.05e-26	114
k141_148184_3	megares|MEG_7165|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	469	604	639	1.05e-26	114
k141_148184_3	megares|MEG_7164|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	469	604	639	1.05e-26	114
k141_148184_3	SARG|gi|1004359922|gb|AMP42228.1|	26.4	469	604	639	3.30e-26	112
k141_148184_3	SARG|AJ295238.gene.p01	24.9	469	604	639	5.85e-26	111
k141_148184_3	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.7	469	604	639	5.85e-26	111
k141_148184_3	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.6	470	604	629	7.54e-26	111
k141_148184_14	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.6	227	262	575	5.45e-21	90.9
k141_148184_14	SARG|gi|948137056|ref|WP_056795395.1|	25.8	194	262	602	1.77e-15	74.7
k141_148184_14	SARG|gi|917203192|ref|WP_051809904.1|	26.6	188	262	620	1.79e-15	74.7
k141_148184_14	SARG|gi|921231571|ref|WP_053176464.1|	26.9	193	262	620	1.79e-15	74.7
k141_148184_14	SARG|gi|926376632|ref|WP_053705806.1|	26.6	188	262	620	1.79e-15	74.7
k141_148184_14	SARG|gi|926351744|ref|WP_053683383.1|	28.1	192	262	648	1.82e-15	74.7
k141_148184_14	SARG|gi|930482089|ref|WP_054228897.1|	26.4	193	262	599	2.38e-15	74.3
k141_148184_14	SARG|gi|985844137|ref|WP_060895163.1|	26.4	193	262	599	2.38e-15	74.3
k141_148184_14	SARG|gi|558888514|ref|WP_023543283.1|	24.9	189	262	615	2.41e-15	74.3
k141_148184_14	SARG|gi|917166849|ref|WP_051773561.1|	26.2	187	262	620	2.42e-15	74.3
k141_146004_3	SARG|gb|AAK76136.1|ARO:3000025|patB	38.1	590	602	588	2.76e-116	357
k141_146004_3	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	33.8	585	602	579	3.17e-96	305
k141_146004_3	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.3	580	602	579	4.80e-95	301
k141_146004_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	35.1	518	602	582	1.44e-94	300
k141_146004_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	33.9	516	602	664	8.49e-93	298
k141_146004_3	SARG|gi|928900436|ref|WP_053931243.1|	32.8	570	602	600	2.81e-91	292
k141_146004_3	SARG|gi|664579989|ref|WP_031094015.1|	32.8	570	602	601	2.89e-91	292
k141_146004_3	SARG|gi|1033217078|gb|OAR27197.1|	32.5	585	602	601	4.05e-91	292
k141_146004_3	SARG|gi|493394434|ref|WP_006350564.1|	31.9	592	602	602	1.60e-90	290
k141_146004_3	SARG|gi|663330365|ref|WP_030329892.1|	32.9	574	602	607	1.82e-90	290
k141_146004_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.6	573	572	575	1.23e-118	362
k141_146004_4	SARG|gb|AAK76137.1|ARO:3000024|patA	35.0	554	572	564	8.73e-109	336
k141_146004_4	SARG|gi|928900436|ref|WP_053931243.1|	30.8	581	572	600	1.64e-73	244
k141_146004_4	SARG|gi|664579989|ref|WP_031094015.1|	30.8	581	572	601	1.68e-73	244
k141_146004_4	SARG|gi|702897513|ref|WP_033300957.1|	31.3	582	572	601	6.36e-73	243
k141_146004_4	SARG|gi|917203192|ref|WP_051809904.1|	29.5	573	572	620	1.85e-72	242
k141_146004_4	SARG|gi|926376632|ref|WP_053705806.1|	29.8	573	572	620	9.75e-72	240
k141_146004_4	SARG|gi|505420018|ref|WP_015607120.1|	30.4	556	572	603	1.85e-71	239
k141_146004_4	SARG|gi|1033217078|gb|OAR27197.1|	29.5	572	572	601	2.48e-71	239
k141_146004_4	SARG|gi|799286378|ref|WP_045936958.1|	29.7	573	572	620	2.64e-71	239
k141_130229_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	48.8	719	710	1162	1.61e-208	617
k141_130229_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	45.3	724	710	1186	1.92e-188	566
k141_130229_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	45.3	724	710	1186	1.92e-188	566
k141_68392_11	SARG|GQ205627.2.gene1.p01	42.4	66	72	525	1.82e-15	67.8
k141_68392_11	SARG|U82085.gene.p01	37.1	70	72	552	1.45e-13	62.4
k141_68392_11	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	SARG|DQ823382.1.gene1.p01	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	SARG|KC539823.1.gene1.p01	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	SARG|AAF24091	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	37.3	67	72	522	1.57e-11	56.6
k141_68392_11	SARG|YP_002332257	37.3	67	72	522	1.57e-11	56.6
k141_68392_12	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	455	455	655	2.87e-55	193
k141_68392_12	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	455	455	655	3.97e-55	193
k141_68392_12	SARG|gb|AKA86814|ARO:3003746|optrA	27.0	455	455	655	3.97e-55	193
k141_68392_12	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	455	455	655	5.49e-55	192
k141_68392_12	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	455	455	655	5.49e-55	192
k141_68392_12	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	455	455	655	7.60e-55	192
k141_68392_12	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	455	455	655	1.05e-54	192
k141_68392_12	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	455	455	655	1.05e-54	192
k141_68392_12	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	455	455	655	1.05e-54	192
k141_68392_12	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.0	455	455	655	1.05e-54	192
k141_68392_15	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	25.9	259	290	304	5.16e-13	67.0
k141_68392_15	SARG|L22689.1.gene1.p01	29.5	183	290	257	6.23e-13	66.2
k141_68392_15	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	25.0	256	290	243	3.96e-11	60.8
k141_102316_11	SARG|YP_001571041	40.2	214	265	648	2.43e-39	143
k141_102316_11	SARG|gi|960873409|ref|WP_058345546.1|	40.2	214	265	648	2.43e-39	143
k141_102316_11	SARG|gi|495067432|ref|WP_007792257.1|	38.1	218	265	647	6.26e-39	142
k141_102316_11	SARG|gi|924626178|ref|WP_053530123.1|	36.8	247	265	648	8.65e-39	142
k141_102316_11	SARG|gi|740610794|ref|WP_038396317.1|	39.7	214	265	648	8.65e-39	142
k141_102316_11	SARG|gi|555268037|ref|WP_023249477.1|	36.8	247	265	648	1.19e-38	141
k141_102316_11	SARG|gi|554685678|ref|WP_023185565.1|	38.4	229	265	648	2.24e-38	140
k141_102316_11	SARG|gi|696411918|ref|WP_032982657.1|	38.1	218	265	647	4.20e-38	140
k141_102316_11	SARG|gi|639216333|ref|WP_024554080.1|	38.8	219	265	648	4.22e-38	140
k141_102316_11	SARG|gi|923061916|ref|WP_053445667.1|	38.0	229	265	648	4.22e-38	140
k141_96361_6	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.3	276	655	1024	3.40e-13	72.0
k141_96361_6	SARG|gb|CAA53189|ARO:3000521|mupA	24.3	276	655	1024	3.40e-13	72.0
k141_96361_6	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.9	276	655	1024	1.34e-12	70.1
k141_96361_6	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.9	276	655	1024	1.34e-12	70.1
k141_96361_6	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	24.8	270	655	1033	1.87e-10	63.2
k141_96361_6	SARG|gb|AEY83581|ARO:3000510|mupB	24.8	270	655	1033	1.87e-10	63.2
k141_96361_6	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	26.1	176	655	1107	7.00e-07	51.6
k141_96361_6	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	26.1	176	655	1107	7.00e-07	51.6
k141_96361_38	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.5	279	272	307	3.27e-34	124
k141_96361_38	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	27.4	303	272	343	5.06e-32	119
k141_96361_38	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	28.0	225	272	325	1.06e-26	105
k141_96361_38	SARG|gb|AAA26793|ARO:3003748|oleC	28.0	225	272	325	2.04e-26	104
k141_96361_38	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	30.3	201	272	293	8.40e-23	94.0
k141_96361_38	SARG|gb|AAR96051.1|ARO:3002894|otrC	31.9	113	272	351	2.98e-17	79.3
k141_96361_38	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	31.9	113	272	351	2.98e-17	79.3
k141_96361_38	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	27.8	187	272	568	4.39e-13	67.8
k141_96361_38	SARG|gb|AAK76137.1|ARO:3000024|patA	26.6	207	272	564	8.44e-12	63.9
k141_96361_38	SARG|gi|498397844|ref|WP_010711245.1|	25.9	185	272	498	1.68e-07	50.8
k141_5164_1	SARG|gi|751264306|ref|WP_040974017.1|	37.1	62	81	646	9.64e-10	52.0
k141_5164_1	SARG|gi|895865878|ref|WP_048974758.1|	35.5	62	81	646	1.32e-09	51.6
k141_117804_4	SARG|gi|817122037|ref|WP_046494699.1|	30.4	217	257	613	1.18e-18	84.0
k141_117804_4	SARG|gi|953808775|ref|WP_058042812.1|	30.7	215	257	608	3.93e-18	82.4
k141_117804_4	SARG|gi|930482089|ref|WP_054228897.1|	31.4	220	257	599	7.13e-18	81.6
k141_117804_4	SARG|gi|985844137|ref|WP_060895163.1|	31.4	220	257	599	7.13e-18	81.6
k141_117804_4	SARG|gi|917172177|ref|WP_051778889.1|	31.2	215	257	620	7.24e-18	81.6
k141_117804_4	SARG|gi|919568551|ref|WP_052871170.1|	31.2	215	257	620	7.24e-18	81.6
k141_117804_4	SARG|gi|921231571|ref|WP_053176464.1|	31.2	215	257	620	7.24e-18	81.6
k141_117804_4	SARG|gi|664556405|ref|WP_031071225.1|	31.3	214	257	602	9.66e-18	81.3
k141_117804_4	SARG|gi|655413091|ref|WP_028811890.1|	32.1	212	257	603	1.77e-17	80.5
k141_117804_4	SARG|gi|496018010|ref|WP_008742581.1|	31.2	215	257	623	1.79e-17	80.5
k141_117804_17	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	232	235	231	1.09e-50	164
k141_117804_17	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.1	232	235	231	4.34e-50	162
k141_117804_17	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.1	232	235	231	4.34e-50	162
k141_117804_17	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.1	232	235	231	1.73e-49	160
k141_117804_17	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.7	232	235	231	3.46e-49	160
k141_117804_17	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.1	231	235	232	5.03e-49	159
k141_117804_17	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.1	231	235	232	5.03e-49	159
k141_117804_17	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	232	235	231	1.10e-47	156
k141_117804_17	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.9	236	235	235	6.93e-47	154
k141_117804_17	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.1	231	235	232	1.79e-46	153
k141_117804_18	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	29.1	220	518	380	1.10e-28	116
k141_117804_18	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.1	220	518	380	1.10e-28	116
k141_21781_4	SARG|gb|APB03219.1|ARO:3003986|TaeA	49.1	646	600	648	3.37e-199	572
k141_21781_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	613	600	655	5.10e-64	221
k141_21781_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	613	600	655	5.10e-64	221
k141_21781_4	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	613	600	655	7.07e-64	221
k141_21781_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	613	600	655	9.80e-64	220
k141_21781_4	SARG|gb|AKA86814|ARO:3003746|optrA	27.4	613	600	655	9.80e-64	220
k141_21781_4	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	613	600	655	3.61e-63	219
k141_21781_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	613	600	655	6.92e-63	218
k141_21781_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	613	600	655	6.92e-63	218
k141_21781_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	613	600	655	6.92e-63	218
k141_102451_28	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.1	670	603	1033	4.80e-29	122
k141_102451_28	SARG|gb|AEY83581|ARO:3000510|mupB	23.1	670	603	1033	4.80e-29	122
k141_102451_28	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.7	672	603	1024	4.64e-28	119
k141_102451_28	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.7	672	603	1024	4.64e-28	119
k141_102451_28	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.7	672	603	1024	4.64e-28	119
k141_102451_28	SARG|gb|CAA53189|ARO:3000521|mupA	23.7	672	603	1024	4.64e-28	119
k141_102451_28	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.7	690	603	1107	5.18e-13	71.2
k141_102451_28	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.7	690	603	1107	5.18e-13	71.2
k141_148458_2	SARG|gb|AAK76136.1|ARO:3000025|patB	38.3	488	489	588	4.64e-110	337
k141_148458_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	50.6	336	489	362	3.52e-107	322
k141_148458_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	38.6	492	489	664	9.42e-102	318
k141_148458_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.8	485	489	582	1.24e-85	273
k141_148458_2	SARG|gi|772774655|ref|WP_045322518.1|	33.7	490	489	620	1.27e-83	269
k141_148458_2	SARG|gi|926356413|ref|WP_053687351.1|	33.3	490	489	620	6.88e-83	267
k141_148458_2	SARG|gi|926345639|ref|WP_053677539.1|	33.3	490	489	620	6.88e-83	267
k141_148458_2	SARG|gi|799286378|ref|WP_045936958.1|	33.3	490	489	620	9.65e-83	267
k141_148458_2	SARG|gi|917127754|ref|WP_051734466.1|	33.3	490	489	620	9.65e-83	267
k141_148458_2	SARG|gi|926294973|ref|WP_053631154.1|	33.3	490	489	620	9.65e-83	267
k141_142766_13	SARG|gi|505420018|ref|WP_015607120.1|	28.7	216	259	603	2.58e-24	100
k141_142766_13	SARG|gi|944152509|ref|WP_055644808.1|	29.4	214	259	616	2.22e-23	97.8
k141_142766_13	SARG|gi|695842130|ref|WP_032755430.1|	28.5	214	259	603	2.97e-23	97.4
k141_142766_13	SARG|gi|702897513|ref|WP_033300957.1|	29.9	214	259	601	5.46e-23	96.7
k141_142766_13	SARG|gi|948137056|ref|WP_056795395.1|	28.5	214	259	602	5.46e-23	96.7
k141_142766_13	SARG|gi|664556405|ref|WP_031071225.1|	29.0	214	259	602	5.46e-23	96.7
k141_142766_13	SARG|gi|558888514|ref|WP_023543283.1|	29.8	218	259	615	5.54e-23	96.7
k141_142766_13	SARG|gi|748767925|ref|WP_040019608.1|	29.8	218	259	623	5.59e-23	96.7
k141_142766_13	SARG|gi|947982677|ref|WP_056642336.1|	29.0	214	259	626	5.60e-23	96.7
k141_142766_13	SARG|gi|639892676|ref|WP_024755698.1|	29.0	214	259	631	5.63e-23	96.7
k141_142766_15	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.0	224	232	228	6.38e-67	205
k141_142766_15	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.6	231	232	232	6.75e-57	179
k141_142766_15	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.6	231	232	232	6.75e-57	179
k141_142766_15	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.6	229	232	231	6.78e-54	172
k141_142766_15	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.2	229	232	229	3.62e-53	170
k141_142766_15	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.2	228	232	231	3.84e-53	170
k141_142766_15	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.9	228	232	231	7.68e-53	169
k141_142766_15	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.8	226	232	231	2.17e-52	168
k141_142766_15	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.8	226	232	231	2.17e-52	168
k141_142766_15	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.3	226	232	219	3.05e-52	167
k141_142766_16	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.8	263	589	367	2.05e-30	121
k141_142766_16	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.8	263	589	368	2.09e-30	121
k141_142766_16	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	27.6	293	589	361	2.94e-29	118
k141_142766_16	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.6	293	589	361	2.94e-29	118
k141_142766_16	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.3	293	589	361	1.84e-28	115
k141_142766_16	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	27.3	293	589	361	1.84e-28	115
k141_142766_16	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.9	216	589	451	3.03e-26	110
k141_142766_16	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.9	225	589	392	5.02e-26	109
k141_142766_16	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.0	226	589	380	5.76e-26	108
k141_142766_16	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.0	226	589	380	5.76e-26	108
k141_142766_21	SARG|gb|ADZ12699.1|ARO:3005091|RanA	38.9	216	358	258	1.44e-42	147
k141_142766_21	SARG|gi|502669352|ref|WP_012905216.1|	35.6	239	358	648	4.25e-42	154
k141_142766_21	SARG|gi|803568669|ref|WP_046077412.1|	35.7	227	358	648	2.86e-41	152
k141_142766_21	SARG|gi|446110352|ref|WP_000188207.1|	35.7	227	358	648	2.86e-41	152
k141_142766_21	SARG|YP_002382193	35.7	227	358	648	2.86e-41	152
k141_142766_21	SARG|gi|803575554|ref|WP_046081557.1|	35.7	227	358	648	2.86e-41	152
k141_142766_21	SARG|gi|446110351|ref|WP_000188206.1|	35.7	227	358	648	2.86e-41	152
k141_142766_21	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.8	201	358	255	8.18e-40	140
k141_142766_21	SARG|gi|1035670474|ref|WP_064517458.1|	34.7	222	358	648	2.15e-38	144
k141_142766_21	SARG|gi|1035717981|ref|WP_064557480.1|	34.7	222	358	648	2.15e-38	144
k141_142766_30	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.8	224	231	231	1.87e-61	191
k141_142766_30	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.2	221	231	228	2.42e-61	191
k141_142766_30	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.6	233	231	232	4.42e-60	187
k141_142766_30	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.6	233	231	232	4.42e-60	187
k141_142766_30	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.0	228	231	233	7.35e-59	184
k141_142766_30	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	225	231	232	3.26e-57	180
k141_142766_30	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.0	231	231	235	3.56e-57	180
k141_142766_30	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.6	227	231	229	2.39e-56	178
k141_142766_30	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.3	227	231	231	5.09e-56	177
k141_142766_30	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.5	229	231	231	1.02e-55	176
k141_142766_31	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	30.1	276	556	365	8.23e-37	139
k141_142766_31	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.1	225	556	380	5.98e-24	102
k141_142766_31	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	225	556	380	5.98e-24	102
k141_142766_31	CARD|gb|CYF42523.1|ARO:3004047|kdpD	31.1	228	556	885	2.28e-21	97.4
k141_105030_1	SARG|gb|CAE00499.1|ARO:3003835|cdeA	43.9	435	458	441	4.83e-114	341
k141_77839_2	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	45.7	221	222	223	1.25e-70	214
k141_77839_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.9	218	222	229	6.66e-39	133
k141_77839_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.6	224	222	231	8.62e-37	127
k141_77839_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.0	224	222	231	1.21e-36	127
k141_77839_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.1	224	222	231	1.71e-36	127
k141_77839_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.1	224	222	231	1.71e-36	127
k141_77839_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.1	224	222	231	6.75e-36	125
k141_77839_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	31.9	226	222	231	5.27e-35	123
k141_77839_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.7	227	222	233	2.18e-34	121
k141_77839_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	29.7	232	222	252	1.31e-29	109
k141_77839_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	59.8	254	256	255	1.85e-103	300
k141_77839_4	SARG|gb|AAV85982.1|ARO:3000535|macB	39.6	222	256	644	2.66e-47	165
k141_77839_4	SARG|gi|803568669|ref|WP_046077412.1|	39.2	237	256	648	1.40e-46	163
k141_77839_4	SARG|gi|446110352|ref|WP_000188207.1|	39.2	237	256	648	1.40e-46	163
k141_77839_4	SARG|YP_002382193	39.2	237	256	648	1.40e-46	163
k141_77839_4	SARG|gi|803575554|ref|WP_046081557.1|	39.2	237	256	648	1.40e-46	163
k141_77839_4	SARG|gi|446110351|ref|WP_000188206.1|	39.2	237	256	648	1.40e-46	163
k141_77839_4	SARG|gi|835233765|ref|WP_047410073.1|	38.6	246	256	648	1.88e-45	160
k141_77839_4	SARG|gi|754951242|ref|WP_042307417.1|	38.6	246	256	648	6.84e-45	158
k141_77839_4	SARG|gi|740856590|ref|WP_038641842.1|	40.1	222	256	648	6.84e-45	158
k141_77839_5	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	22.9	681	676	641	3.88e-31	128
k141_117962_7	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.0	225	233	225	5.57e-65	200
k141_117962_7	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.0	225	233	225	5.57e-65	200
k141_117962_7	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.5	227	233	229	1.94e-44	147
k141_117962_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.7	229	233	231	2.90e-44	147
k141_117962_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.5	223	233	228	1.87e-41	140
k141_117962_7	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.6	223	233	231	1.13e-40	138
k141_117962_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.3	228	233	232	1.16e-40	138
k141_117962_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.3	228	233	232	1.16e-40	138
k141_117962_7	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.4	223	233	230	2.43e-39	134
k141_117962_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.5	228	233	232	1.01e-38	133
k141_117962_8	CARD|gb|CYF42523.1|ARO:3004047|kdpD	32.0	879	899	885	1.60e-155	478
k141_117962_8	SARG|gb|AAG05187.1|ARO:3005067|ParS	27.7	220	899	428	6.14e-14	73.9
k141_117962_8	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.9	218	899	361	1.62e-10	62.8
k141_117962_23	SARG|gi|1045390184|ref|WP_065479071.1|	31.9	473	553	605	9.28e-57	199
k141_117962_23	SARG|gi|664170108|ref|WP_030704355.1|	31.9	470	553	603	6.11e-55	194
k141_117962_23	SARG|gi|490068471|ref|WP_003970646.1|	31.8	471	553	603	6.11e-55	194
k141_117962_23	SARG|gi|695842130|ref|WP_032755430.1|	31.3	473	553	603	1.17e-54	193
k141_117962_23	SARG|gi|501350226|ref|WP_012381861.1|	31.8	471	553	603	1.17e-54	193
k141_117962_23	SARG|gi|505420018|ref|WP_015607120.1|	31.3	473	553	603	1.17e-54	193
k141_117962_23	SARG|gi|663155409|ref|WP_030194633.1|	31.4	477	553	605	1.21e-54	193
k141_117962_23	SARG|gi|664538723|ref|WP_031054357.1|	31.4	477	553	605	1.21e-54	193
k141_117962_23	SARG|gi|663330365|ref|WP_030329892.1|	31.4	477	553	607	1.25e-54	193
k141_117962_23	SARG|gi|664317010|ref|WP_030845774.1|	31.4	477	553	605	2.30e-54	192
k141_117962_24	SARG|gi|953808775|ref|WP_058042812.1|	46.8	94	113	608	2.86e-21	86.3
k141_117962_24	SARG|gb|AYV52072.1|ARO:3002882|lmrD	40.8	98	113	664	1.06e-18	79.0
k141_117962_24	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.5	78	113	255	2.30e-06	43.5
k141_46610_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.8	543	634	1024	3.93e-61	219
k141_46610_1	SARG|gb|CAA53189|ARO:3000521|mupA	27.8	543	634	1024	3.93e-61	219
k141_46610_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	27.8	543	634	1024	5.34e-61	218
k141_46610_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.8	543	634	1024	5.34e-61	218
k141_105207_1	SARG|AM180355.1.gene636.p01	25.0	660	689	639	9.05e-45	169
k141_105207_1	SARG|ABI81214	24.5	658	689	639	4.17e-44	167
k141_105207_1	SARG|X04388.gene.p01	24.3	658	689	639	4.17e-44	167
k141_105207_1	SARG|BAB71968	24.3	658	689	639	1.04e-43	166
k141_105207_1	SARG|YP_002738300	24.3	658	689	639	1.41e-43	165
k141_105207_1	SARG|ABB70054	24.3	658	689	639	3.51e-43	164
k141_105207_1	SARG|gi|319894056|gb|ADV76307.1|	24.3	658	689	639	1.18e-42	162
k141_86879_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.1	226	226	231	3.91e-54	172
k141_86879_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.4	222	226	219	4.53e-50	161
k141_86879_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.2	228	226	232	4.68e-50	162
k141_86879_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.2	230	226	232	1.50e-45	150
k141_86879_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.2	230	226	232	1.50e-45	150
k141_86879_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.0	220	226	219	9.31e-44	145
k141_86879_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.0	220	226	220	9.58e-44	145
k141_86879_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.0	220	226	220	1.35e-43	145
k141_86879_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.5	220	226	219	7.39e-43	143
k141_86879_3	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	34.6	228	226	230	1.42e-42	142
k141_86879_4	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.5	235	496	381	6.87e-27	110
k141_86879_4	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.5	235	496	381	6.87e-27	110
k141_86879_4	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	237	496	381	3.19e-26	108
k141_86879_4	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	237	496	381	3.19e-26	108
k141_86879_4	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.4	285	496	365	1.16e-23	101
k141_86879_4	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.6	238	496	359	1.21e-22	98.2
k141_86879_4	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.0	230	496	364	1.43e-21	95.1
k141_86879_4	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.0	230	496	364	1.43e-21	95.1
k141_86879_4	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.5	291	496	370	3.76e-21	94.0
k141_86879_4	CARD|gb|AEX49906.1|ARO:3003583|basS	27.2	239	496	477	1.15e-14	75.1
k141_30718_2	SARG|gi|445996719|ref|WP_000074574.1|	29.8	262	289	309	1.51e-32	120
k141_30718_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.4	226	289	255	9.56e-32	117
k141_30718_2	SARG|ZP_04081918	29.7	286	289	306	2.85e-31	117
k141_30718_2	SARG|gi|507055561|ref|WP_016126482.1|	29.1	258	289	309	4.22e-31	117
k141_30718_2	SARG|gi|447057509|ref|WP_001134765.1|	29.1	258	289	309	4.22e-31	117
k141_30718_2	SARG|gi|445996695|ref|WP_000074550.1|	30.6	222	289	309	5.88e-31	116
k141_30718_2	SARG|gi|884875933|emb|CKG93789.1|	29.1	258	289	309	5.88e-31	116
k141_30718_2	SARG|gi|445996696|ref|WP_000074551.1|	30.6	222	289	309	5.88e-31	116
k141_30718_2	SARG|gi|447195835|ref|WP_001273091.1|	29.4	286	289	306	7.74e-31	116
k141_30718_2	SARG|gi|507035724|ref|WP_016107411.1|	30.6	222	289	309	8.20e-31	116
k141_30718_3	SARG|gi|671541568|ref|WP_031525212.1|	33.6	262	284	648	3.26e-31	121
k141_30718_3	SARG|gi|742378414|ref|WP_038857601.1|	33.6	262	284	647	2.44e-29	115
k141_30718_3	SARG|gi|506220920|ref|WP_015740695.1|	33.6	262	284	647	3.31e-29	115
k141_30718_3	SARG|gi|746253210|ref|WP_039301529.1|	34.4	227	284	648	3.32e-29	115
k141_30718_3	SARG|gi|746243059|ref|WP_039291473.1|	34.8	227	284	648	4.52e-29	115
k141_30718_3	SARG|gi|495736522|ref|WP_008461101.1|	33.9	227	284	648	1.13e-28	114
k141_30718_3	SARG|gi|1001720867|ref|WP_061274204.1|	33.9	227	284	648	1.13e-28	114
k141_30718_3	SARG|gi|696411918|ref|WP_032982657.1|	34.5	229	284	647	2.84e-28	112
k141_30718_3	SARG|gi|639209604|ref|WP_024547784.1|	34.9	229	284	648	2.84e-28	112
k141_30718_3	SARG|gi|938460528|ref|WP_054624864.1|	33.2	262	284	647	5.24e-28	112
k141_30718_4	SARG|gb|APB03216.1|ARO:3003982|LlmA	61.3	282	288	287	2.78e-135	383
